Objective Many autoantibodies are known to be associated with SLE, although their role in clinical practice is limited because of low sensitivity and weak associations with clinical manifestations.

Purpose: Chromosomal microarray (CMA) testing provides the highest diagnostic yield for clinical testing of patients with developmental delay (DD), intellectual disability (ID), multiple congenital ...

Microarray-based comparative genomic hybridization (CGH microarray) is an evolving technology for the rapid multiplex detection of genomic imbalances. 1 This diagnostic strategy has contributed to our ...

CombiMatrix, a CLIA-certified laboratory, is bringing microarray analysis to the underserved problem of recurrent pregnancy loss as well as to prenatal testing. CombiMatrix performs microarray assays ...

Objectives Current evidence recommend Microarray testing as first-tier investigation for Children with developmental Delay and moderate to severe intellectual disability. Our aim is to see the ...

JA Rosenfeld is an employee of Signature Genomic Laboratories, a subsidiary of PerkinElmer, Inc. The authors have no other relevant affiliations or financial involvement with any organization or ...

As per precedence Research, the global DNA microarray market size is projected to grow approximately USD 6.13 billion by 2034 from valued at USD 2.28 billion in 2023. It is expanding at a CAGR of 9.4% ...

This was originally written as a programming test, though I thought the code would be better off published in case others wish to use this (especially between academia and students). The original data ...